Temtokibart

• CAT Number: I040393
• CAS Number: 2639874-57-8
• Purity: ≥95%

Temtokibart(CAT: I040393) is a fully human IgG1 λ₂ monoclonal antibody targeting the IL‑22RA1 receptor subunit, developed through a collaboration between argenx and LEO Pharma. By blocking IL‑22RA1, it inhibits signaling by IL‑22, IL‑20, and IL‑24, molecules implicated in skin barrier dysfunction and inflammation associated with atopic dermatitis. In a Phase 2a trial, temtokibart showed rapid improvements in skin hydration and barrier markers—comparable to dupilumab—with molecular effects observed as early as week 1. A larger Phase 2b study (NCT05923099) recently met its primary endpoint, demonstrating a significant reduction in Eczema Area and Severity Index (EASI) scores at 16 weeks across several doses, with the treatment being well-tolerated. Supplied at high purity for advanced dermatology and immunology research.